JOHNATHAN M LANCASTER
Medical Practice in Tampa, FL
License number
Florida 91553
Issued Date
Sep 21, 2004
Effective Date
Feb 1, 2017
Expiration Date
Jan 31, 2017
Category
Health Care
Type
Medical Doctor
Address
Address
12902 Magnolia Dr, Tampa, FL 33612
Phone
(813) 745-4734
Organization information
See more information about JOHNATHAN M LANCASTER at bizstanding.comH Lee Moffitt Cancer Center - John V Kiluk MD
4117 E Fowler Ave, Tampa, FL 33617
Doing business as:
H Lee Moffitt Cancer Center - Johnathan M Lancaster MD<br>H Lee Moffitt Cancer Center - Nazanin Khapour MD
Phone:
(813) 745-6769 (Phone)
Categories:
Oncology Physicians & Surgeons, Physicians & Surgeons
Professional information
Dr. Johnathan M Lancaster, Tampa FL - MD (Doctor of Medicine)
Specialties:
Gynecologic Oncology
Address:
Moffitt Cancer Center
12902 Usf Magnolia Dr, Tampa 33612
(813) 745-4673 (Phone), (813) 449-8210 (Fax)
12902 Usf Magnolia Dr, Tampa 33612
(813) 745-4673 (Phone), (813) 449-8210 (Fax)
Procedures:
Gynecological Oncology Surgery
Conditions:
Gynecological Cancers, Ovarian Cancer
Certifications:
Gynecological Oncology, Obstetrics & Gynecology
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Moffitt Cancer Center
12902 Usf Magnolia Dr, Tampa 33612
H. Lee Moffitt Cancer Center and Research Institute I.
12902 Usf Magnolia Dr, Tampa 33612
12902 Usf Magnolia Dr, Tampa 33612
H. Lee Moffitt Cancer Center and Research Institute I.
12902 Usf Magnolia Dr, Tampa 33612
Philosophy:
"Dr. Lancaster's research is focused on the molecular genetic etiology of ovarian cancer development, progression and response to therapy." Dr. Johnathan Lancaster is a gynecologic oncologist as well as the President of the Moffitt Medical Group. As a physician-scientist, Dr. Lancaster finds gynecologic oncology a gratifying and challenging field, both at the clinical level helping patients one on one, and in research, where the rapid discovery continually advances knowledge about treatment.
Education:
Medical School
University Of Wales
Graduated: 1997
Graduated: 1993
Addenbrooke's Hospital, Cambrige University
Graduated: 1994
Duke University Medical Center
Graduated: 2000
Duke University Medical School
Graduated: 2003
Graduated: 1991
University Of Wales, PHD
Graduated: 2005
University Of Wales
Graduated: 1997
Graduated: 1993
Addenbrooke's Hospital, Cambrige University
Graduated: 1994
Duke University Medical Center
Graduated: 2000
Duke University Medical School
Graduated: 2003
Graduated: 1991
University Of Wales, PHD
Graduated: 2005
Individualized Cancer Treatments
US Patent:
2010030, Dec 2, 2010
Filed:
Apr 16, 2010
Appl. No.:
12/761866
Inventors:
Johnathan M. Lancaster - Tampa FL, US
Joseph R. Nevins - Chapel Hill NC, US
Joseph R. Nevins - Chapel Hill NC, US
Assignee:
Duke University - Durham NC
University of South Florida - Tampa FL
University of South Florida - Tampa FL
International Classification:
C12Q 1/68, A61K 31/4375, A61K 31/704, A61K 31/664, A61K 31/7068, A61K 31/337, A61P 35/00
US Classification:
514 34, 435 6, 514281, 514110, 514 49, 514449
Abstract:
The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments.
Individualized Cancer Treatments
US Patent:
2007017, Jul 26, 2007
Filed:
Sep 28, 2006
Appl. No.:
11/541165
Inventors:
Johnathan Lancaster - Tampa FL, US
Joseph Nevins - Chapel Hill NC, US
Joseph Nevins - Chapel Hill NC, US
Assignee:
University of South Florida - Tampa FL
Duke University - Durham NC
Duke University - Durham NC
International Classification:
C12Q 1/68, C12M 1/34
US Classification:
435006000, 435287200
Abstract:
The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments.
Micro-Rna Profiles Associated With Endometrial Cancer Development And Response To Cisplatin And Doxorubicin Chemotherapy
US Patent:
8257919, Sep 4, 2012
Filed:
Aug 3, 2009
Appl. No.:
12/534493
Inventors:
Johnathan M. Lancaster - Tampa FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
C12Q 1/68
US Classification:
435 6, 435325, 435375, 514 44
Abstract:
A method predicting of cancer chemoresponse of the population of cancer cells to the one or more chemotherapeutic agents. Our ability to treat patients with advanced stage and recurrent endometrial cancer is hampered by an incomplete understanding of the molecular basis of disease development and response to therapy. A novel class of gene products called microRNA (miRNA) has recently been implicated in the etiology of several different human cancers. Altered levels of expression of specific miRNAs may contribute to cancer development in a variety of cancers such as endometrial cancer and may also influence response to cytotoxic chemotherapy or other cancer treatments. Evidence is provided that differential expression of miRNAs contributes to endometrial carcinogenesis and further associates with sensitivity of endometrial cancer cells to various chemotherapeutic agents including cisplatin and doxorubicin chemotherapy. MiRNA profiles and their gene targets show promise as biomarkers of endometrial cancer chemo-response, and as a novel class of therapeutic targets for patients with endometrial cancer.
Cancer Platinum Resistance Detection And Sensitization Method
US Patent:
2011016, Jul 7, 2011
Filed:
Dec 22, 2010
Appl. No.:
12/975970
Inventors:
Johnathan M. Lancaster - Tampa FL, US
Douglas C. Marchion - Seminole FL, US
Douglas C. Marchion - Seminole FL, US
Assignee:
H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa FL
University of South Florida - Tampa FL
University of South Florida - Tampa FL
International Classification:
A61K 31/7064, C12Q 1/02, C40B 30/06, A61P 35/00
US Classification:
514 49, 435 29, 506 10
Abstract:
The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
Luminescence Characterization Of Quantum Dots Conjugated With Biomarkers For Early Cancer Detection
US Patent:
2006000, Jan 5, 2006
Filed:
Jun 30, 2005
Appl. No.:
11/160617
Inventors:
Tatyana Zhukov - Lutz FL, US
Sergei Ostapenko - Wesley Chapel FL, US
Rebecca Sutphen - Tampa FL, US
Johnathan Lancaster - Tampa FL, US
Thomas Sellers - Tampa FL, US
Jin Zhang - Santa Cruz CA, US
Sergei Ostapenko - Wesley Chapel FL, US
Rebecca Sutphen - Tampa FL, US
Johnathan Lancaster - Tampa FL, US
Thomas Sellers - Tampa FL, US
Jin Zhang - Santa Cruz CA, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
G01N 33/551
US Classification:
436524000
Abstract:
Luminescent semiconductor quantum dots (QDs) conjugated with biomolecules to serve as sensitive probes for early detection of the cancer cells, specifically for ovarian cancer and lung cancer, which represents the most lethal malignancies. The luminescence characterization of the bin-conjugated QDs with cancer specific antigens using linkage molecules. Photo-enhancement is measured at various laser density power, temperatures and laser wavelengths.
Method Of Predicting Chemotherapeutic Responsiveness Of Cancer
US Patent:
2010029, Nov 18, 2010
Filed:
Apr 23, 2010
Appl. No.:
12/765995
Inventors:
Johnathan M. Lancaster - Tampa FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
C40B 30/02, G06G 7/48
US Classification:
506 8, 703 11
Abstract:
Disclosed is a method of predicting clinical tumor outcome by providing gene expression from a tumor sample. The method utilizes a novel genetic screen to identify genes that contribute to chemotherapeutic responsiveness, using formalin fixed paraffin embedded clinical samples of epithelial cancer, specifically serous ovarian cancer. The method is useful in predicting tumor responsiveness to chemotherapeutics, including alkylating agents, cisplatin, antimetabolites, plant alkaloids, and antitumor antibiotics. A microarray screen showed formalin fixed paraffin embedded samples can identify genes related to chemotherapeutic response with 86% efficiency.
Methods And Materials For Detection, Diagnosis And Management Of Ovarian Cancer
US Patent:
2010019, Jul 29, 2010
Filed:
Jan 25, 2008
Appl. No.:
12/524537
Inventors:
Rebecca Sutphen - Tampa FL, US
Johnathan Mark Lancaster - Tampa FL, US
Johnathan Mark Lancaster - Tampa FL, US
International Classification:
C40B 40/10, G01N 33/53, G01N 33/50
US Classification:
506 18, 435 71, 436 86, 435 792
Abstract:
The subject invention concerns methods using a panel of proteins to detect, diagnose, and monitor therapy during treatment of ovarian cancer in a female patient. The proteins were identified using proteomics analyses of plasma samples obtained preoperatively from ovarian cancer patients versus those of healthy control women. Such a panel has utility for the diagnosis of ovarian cancer, screening for ovarian cancer and possibly therapeutic monitoring.
Human Cancer Micro-Rna Expression Profiles Predictive Of Chemo-Response
US Patent:
2013005, Mar 7, 2013
Filed:
Mar 11, 2011
Appl. No.:
13/634028
Inventors:
Johnathan Mark Lancaster - Tampa FL, US
Yin Xiong - Lutz FL, US
Ning Chen - Tampa FL, US
Yin Xiong - Lutz FL, US
Ning Chen - Tampa FL, US
Assignee:
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE - TAMPA FL
International Classification:
A61K 33/24, C40B 30/04, C12N 5/09, C40B 40/06, A61P 35/00, A61K 31/704, A61K 31/337, A61K 31/7068, A61K 31/4745, C12Q 1/68, A61K 31/282
US Classification:
424649, 435 612, 435 611, 506 9, 435375, 506 16, 514492, 514 34, 514449, 514 49, 514283
Abstract:
Disclosed are identified and successfully targeted microRNAs (miRNAs) associated with human cancer cell line response to a range of anti-cancer agents. The strategy of integrating in vitro miRNA expression and drug sensitivity data not only aid in the characterization of determinants of cytotoxic response, but also in the identification of novel therapeutic targets.
Gene Expression Signatures For Oncogenic Pathway Deregulation
US Patent:
2009018, Jul 23, 2009
Filed:
May 15, 2006
Appl. No.:
11/920377
Inventors:
Joseph R. Nevins - Chapel Hill NC, US
Andrea H. Bild - Salt Lake City UT, US
Guang Yao - Raleigh NC, US
Jeffrey T. Chang - Durham NC, US
Quanli Wang - Durham NC, US
Anil Potti - Chapel Hill NC, US
David Harpole - Durham NC, US
Johnathan M. Lancaster - Tampa FL, US
Andrew Berchuck - Chapel Hill NC, US
John A. Olson - Chapel Hill NC, US
Jeffrey R. Marks - Hillsborough NC, US
Mike West - Durham NC, US
Holly Dressman - Durham NC, US
Andrea H. Bild - Salt Lake City UT, US
Guang Yao - Raleigh NC, US
Jeffrey T. Chang - Durham NC, US
Quanli Wang - Durham NC, US
Anil Potti - Chapel Hill NC, US
David Harpole - Durham NC, US
Johnathan M. Lancaster - Tampa FL, US
Andrew Berchuck - Chapel Hill NC, US
John A. Olson - Chapel Hill NC, US
Jeffrey R. Marks - Hillsborough NC, US
Mike West - Durham NC, US
Holly Dressman - Durham NC, US
International Classification:
A61K 39/395, C12Q 1/68, C40B 30/00, A61K 31/4709
US Classification:
4241341, 435 6, 506 7, 514314
Abstract:
The disclosure relates to identifying deregulated pathways in cancer. In certain embodiments, the methods of the disclosure can be used to evaluate therapeutic agents for the treatment of cancer.